A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous Administration

Phase 1

Completed

• Conditions: Healthy Volunteers
• Interventions: Drug: PEG-IFN alfa-2a BA-free formulation (Test); Drug: PEG-IFN alfa-2a market formulation (Reference)

• Registration Number: NCT02573025
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This is an open-label, randomized, multi-center, single dose, two-period, two-sequence crossover study to investigate the bioequivalence of PEG-IFN alfa-2a BA-free formulation versus the reference market formulation (PEG-IFN alfa-2a \[Pegasys®\]) following subcutaneous administration via prefilled syringe in healthy Chinese participants.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-09-17
• Study First Submitted: 2015-10-08
• Study First Submitted QC: 2015-10-08
• Study First Posted: 2015-10-09
• Primary Completion: 2016-04-11
• Study Completion: 2016-04-11
• Status Verified: 2017-03
• Last Update Submitted: 2017-03-10
• Last Update Posted: 2017-03-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 277

Inclusion Criteria

• Healthy female and male Chinese participants
• Body mass index between 19 and 28 kilograms per square meter (kg/m^2), inclusive
• Participants determined as healthy by their medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory measurements performed at the Screening visit
• Female participants of childbearing potential: willing to use highly effective methods of contraception throughout the study and for 90 days after the last dosing
• Male participants: agreement to remain abstinent or use spermicide and barrier method contraception throughout the study and for 90 days after the last dosing
• Able to participate and willing to give written informed consent and to comply with the study restrictions

Read More

Exclusion Criteria

• Any clinically relevant condition or history of cardiovascular, psychiatric, gastrointestinal, respiratory, renal, hepatic, hematological, lymphatic, neurological (including seizure history), musculoskeletal, genitourinary, immunological, metabolic, malignant, or dermatological disorder
• Participants who are positive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti HCV) or human immunodeficiency virus I and II antibody (anti-HIV I, anti-HIV II) tests at Screening
• Participants with alanine aminotransferase (ALT) above the upper limit of normal at Screening or on Day -1 of Period 1
• Any other condition or disease (other than those already stated) which, in the judgment of the Investigator, would place the participant at undue risk, interfere with the absorption, distribution, metabolism, and excretion of PEG-IFN alfa-2a, or interfere with the ability of the participant to complete the study
• History of drug or alcohol abuse within the last year before screening
• Treatment with interferon or PEG-IFN alfa-2a within 3 months prior to the first dosing
• Female participants who are pregnant, currently lactating, or have a positive serum pregnancy test at screening or have a positive urine pregnancy test on Day -1 of Period 1
• Use of any prescribed or over the counter medication or herbal medicine taken within 14 days prior to the first dosing or within 5 times the elimination half-life of the medication prior to the first dosing (whichever is longer). Exceptions are paracetamol, the contraceptive pill, hormone replacement therapy and commonly used vitamin supplements, which are permitted
• Regular smoking with consumption of more than 10 cigarettes per day or an equivalent amount of tobacco
• Participation in an investigational drug or device study within 3 months prior to the first dosing

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Reference Followed by Test	PEG-IFN alfa-2a BA-free formulation (Test)	Participants will receive PEG-IFN alfa-2a market formulation (Reference) in Period 1, followed by PEG-IFN alfa-2a BA-free formulation (Test) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
Reference Followed by Test	PEG-IFN alfa-2a market formulation (Reference)	Participants will receive PEG-IFN alfa-2a market formulation (Reference) in Period 1, followed by PEG-IFN alfa-2a BA-free formulation (Test) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
Test Followed by Reference	PEG-IFN alfa-2a BA-free formulation (Test)	Participants will receive PEG-IFN alfa-2a BA-free formulation (Test) in Period 1, followed by PEG-IFN alfa-2a market formulation (Reference) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
Test Followed by Reference	PEG-IFN alfa-2a market formulation (Reference)	Participants will receive PEG-IFN alfa-2a BA-free formulation (Test) in Period 1, followed by PEG-IFN alfa-2a market formulation (Reference) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.

Primary Outcome Measures

Name	Time	Method
Maximum Observed Concentration (Cmax) for PEG-IFN alfa-2a	Predose (-1 Hour), Hour 1, 3, 5, 8, 12, 24, 48, 72, 84, 96, 120, 144, 168, 192, 216, 240, 312, 384, 480, 552, 648, 816 post Dose
Area Under the Concentration-Time Curve (AUC) for PEG-IFN alfa-2a From Time Zero to 816 hours (AUC0-816h)	Predose (-1 Hour), Hour 1, 3, 5, 8, 12, 24, 48, 72, 84, 96, 120, 144, 168, 192, 216, 240, 312, 384, 480, 552, 648, 816 post Dose

Secondary Outcome Measures

Name	Time	Method
Area Under the Concentration-Time Curve for PEG-IFN alfa-2a From Time Zero Extrapolated to Infinity (AUC0-inf)	Predose (-1 Hour), Hour 1, 3, 5, 8, 12, 24, 48, 72, 84, 96, 120, 144, 168, 192, 216, 240, 312, 384, 480, 552, 648, 816 post Dose
Time to Reach Cmax (tmax) for PEG-IFN alfa-2a	Predose (-1 Hour), Hour 1, 3, 5, 8, 12, 24, 48, 72, 84, 96, 120, 144, 168, 192, 216, 240, 312, 384, 480, 552, 648, 816 post Dose
Terminal Half-Life (t1/2) for PEG-IFN alfa-2a	Predose (-1 Hour), Hour 1, 3, 5, 8, 12, 24, 48, 72, 84, 96, 120, 144, 168, 192, 216, 240, 312, 384, 480, 552, 648, 816 post Dose
Percentage of Participants With Adverse Events	Baseline up to 35 days post last dose of PEG-IFN alfa-2a (maximum up to 17.5 weeks)

Trial Locations

Locations (9)

The University of Hong Kong; Pharmacy Clinical Trials; 🇭🇰 Hong Kong, Hong Kong

Christchurch Clinical Studies Trust; 🇳🇿 Christchurch, New Zealand

Auckland Clinical Studies Limited; 🇳🇿 Grafton, New Zealand

SingHealth Investigational Medicine Unit; Haematology; 🇸🇬 Singapore, Singapore

China Medical University Hospital;Oncology and Hematology Office Critical Care Center, 14H; 🇨🇳 Taichung, Taiwan

Changi General Hospital- Parent; Department of Rheumatology; 🇸🇬 Singapore, Singapore

Taipei Medical University Hospital; Clinical Research Center; 🇨🇳 Taipei City, Taiwan

CMAX A division of IDT Australia Limited; 🇦🇺 Adelaide, South Australia, Australia

The Chinese University of Hong Kong; Emergency Medicine; 🇭🇰 Shatin, Hong Kong